Global Gamma Delta T Cell Cancer Therapy Market By Clinical Indication, Therapies, Clinical Trials and Region (Including COVID-19 Impact Analysis): A Report by Absolute Markets Insights

PUNE, India, March 14, 2022 /PRNewswire/ -- A new generation of therapies based on gamma delta T cells, a special type of immune cell, has the potential to cure cancer more effectively and with fewer side effects. T-cell immunotherapies, particularly CAR-T cells, are becoming increasingly popular in the treatment of cancer. These genetically engineered T cells have demonstrated impressive remission rates in individuals who have failed to react to conventional therapy. There is a surge of study focusing on a rare form of T cell among the different solutions developing. Gamma delta T cells make up just around 5% of total T cells in our bodies, yet they play a crucial role in cancer prevention. The ensuing rise in cancer prevalence and cancer immunotherapies have emerged as a popular treatment choice among a variety of treatment alternatives, demonstrating their effectiveness against a wide range of cancers. The development of a number of novel therapeutic techniques and companies adopting advanced technologies that harness multiple parts of the immune system to treat cancer has emerged from advances in knowledge of the dynamic interplay between the immune system and cancer. With these continuous advancements, the global gamma delta T cell cancer therapy market is flourishing globally.

Read our 420+ pages report on Medical Commodes Market published by Absolute Markets Insights

Clinical Indication

In the last ten years, cancer has been amongst the leading causes of death globally. According to World Health Organization (WHO), there were 10 million deaths in 2020 and the most common cancers were breast cancer with 2.26 million, followed by prostate cancer with 1.41 million and skin cancer with 1.20 million. The T cell subset of gamma delta T cells has the potential to overcome numerous challenges in cancer therapy, particularly for cancers that have no recognized treatment, lack tumor-specific antigens for antibody and CAR-T targeting, or are resistant to immune checkpoint inhibitors. The extraordinary effectiveness of modified T cells in the treatment of hematological malignancies has transformed adoptive cell immunotherapy. Furthermore, prostate cancer is also increasing at an alarming rate amongst the male population. The recent developments in the gamma delta T cell cancer therapy market has proven to be effective in eradicating the cancer cells and solid tumors including prostate cancer.   As a result, significant efforts are being made to apply this promising technology to the treatment of solid tumor and other cancers with the development of allogeneic medicines.

Get PDF sample report with related graphs & charts (Pre & post COVID-19 impact analysis): https://www.absolutemarketsinsights.com/request_sample.php?id=1084

Therapies

GDXO12 is a non-engineered allogeneic variable delta 1 gamma-delta T cell treatment made from healthy donor blood, a subgroup of T lymphocytes that recognise and respond to dysregulated molecular patterns on cancer cells. The FDA has designated GDX012 as an orphan medication for the treatment of acute myeloid leukemia (AML).  Acute myeloid leukemia (AML) is amongst the most common form of cancer across older people. In September 2021, Gamma Delta Therapeutics Ltd. (GDT), a biotechnology firm pioneering the research and development of allogeneic gamma delta T cell treatments for cancer, announced that it has started a first-in-human Phase I clinical study for GDX012 to treat acute myeloid leukemia (AML). Such initiatives by leading players is boosting the growth of global gamma delta T cell cancer therapy market.

Clinical Trials

Various pre-clinical biotechnology companies are working on gamma-delta T-cell therapies to enhance their results for cancer treatments, which is fueling the growth of global gamma delta T cell cancer therapy market. Companies are looking forward to enhance their gamma delta T cell cancer therapy offering by collaborating. For instance, In October 2021, Kiromic BioPharma, Inc., a pre-clinical stage biotechnology company that uses its proprietary DIAMOND artificial intelligence (AI) platform to improve drug discovery and development with a therapeutic focus on immuno-oncology, announced a strategic partnership with Gemelli Teaching Hospital IRCCS to speed up the analysis of the company's first allogeneic CAR-T clinical trial.

Speak to our analyst in case of queries before buying this report: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=1084

Regional Analysis

Asia Pacific is anticipated to witness fastest growth in the global gamma delta T cell cancer therapy market over the forecast period. Each year, Asia Pacific is responsible to half of the world's new cancer cases, and cancer-related fatalities in Asia are anticipated to rise by 36% by 2030. Prostate cancer is becoming one of the major male cancers in various Asian countries, while Asia Pacific has the world's highest prevalence of liver and stomach cancers. Thus, in order to reduce these numbers, government organizations and healthcare institutions are investing heavily into cancer therapies. Moreover the leading players in the market are investing into continuous research and development for gamma delta T cell cancer therapy since they have witnessed an encouraging response and positive results. A number of preclinical studies have been initiated by researchers for exploiting the role of gamma delta T cell cancer therapy in various types of cancer. Thus similar investments towards these advancements showcases potential growth opportunities for global gamma delta T cell cancer therapy market over the period of next eight years.

Request for customization to meet your precise research requirements: https://www.absolutemarketsinsights.com/request_for_customization.php?id=1084

Global Gamma Delta T Cell Cancer Therapy Market Research Scope:

View our exclusive press releases on Industry Global News24

Global Gamma Delta T Cell Cancer Therapy Market:

• By Clinical Indication
• Solid Tumor
• Hematological Cancer
• Non-Hodgkin's lymphoma
• Multiple Myeloma
• Chronic lymphocytic leukemia and Melanoma
• Pancreatic Cancer
• Prostate Cancer
• Colorectal Cancer
• Others
• By Therapies
• ADI-001
• LAVA-051
• INB-200
• TCB002
• INB-100
• GDX012
• AVM0703
• Others
• By Clinical Trials
• Research
• Preclinical
• Phase-I
• Phase-II/III

Purchase the latest in-depth Gamma Delta T Cell Cancer Therapy Market Report @ https://www.absolutemarketsinsights.com/checkout?id=1084

• By Region
• North America (U.S., Canada, Mexico, Rest of North America)
• Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
• Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
• Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
• Latin America (Brazil, Argentina, Rest of Latin America)

Browse more trending reports by Absolute Markets Insights:

• Live Cell Encapsulation Market – Global live cell encapsulation market was valued at US$ 285 Mn in 2020 and is anticipated to accelerate at a CAGR of 3.2% over the forecast period.
• PD-1 And PD-L1 Inhibitors Market – Global PD-1 and PD-L1 inhibitors market generated a revenue of US$ 28,497.82 Mn in 2020 and is estimated to witness a CAGR of 18.8% over the forecast period.
• T-Cell Therapy Market – Global T-cell therapy market is anticipated to grow at a CAGR of 12.45% over the forecast period.
• Dendritic Cell Cancer Vaccine Immunotherapy Market – Global dendritic cell cancer vaccine immunotherapy market is estimated to clock a CAGR of 14.4% over the forecast period.
• Metastatic Colorectal Cancer Market- Global Metastatic Colorectal Cancer Market is growing at a CAGR of 9.81% over the forecast period.
• MRNA Vaccines Market- Global mRNA vaccine market is growing at a CAGR of 19.76% over the forecast period.

Glance through Absolute Markets Insights plethora of reports on Healthcare Category

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.

From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Contact Name: Shreyas Tanna
Company: Absolute Markets Insights
Email Id: sales@absolutemarketsinsights.com 
Phone: IN +91-7400-24-24-24, US +1-510-420-1213
Website: www.absolutemarketsinsights.com

Logo: https://mma.prnewswire.com/media/1761877/AMI_Logo.jpg